Weight Outcome in Infants with Prolonged Hyperinsulinemic Hypoglycemia Treated with Diazoxide versus those with Spontaneous Resolution

Suresh Chandran1, Victor Samuel Rajadurai1, Chng Hui Yi1, Joyce Lim2, Fabian Yap2
Department of Neonatology1 and Department of Endocrinology2, KK Women’s and Children’s Hospital, SINGAPORE
DukeNUS Medical School, Lee Kong Chian School of Medicine NTU, Yong Loo Lin School of Medicine NUS, SINGAPORE

BACKGROUND
- Physiological transition of glucose metabolism is typically completed within 48-72h of life, yet prolonged hypoglycemia beyond 5d of life is not uncommonly encountered, especially in infants at-risk of hypoglycemia.
- Hyperinsulinemic hypoglycemia (HH) may be a cause of prolonged hypoglycemia. It is characterized by high GIR >10mg/kg/min to maintain normoglycemia (3.5–5.9mmol/L). During hypoglycaemia, HH infants have inappropriate insulin & c-peptide levels, hypoketonemia and hypofattyacidemia.
- Management of HH includes feeding and dextrose infusion while awaiting spontaneous resolution (SR) or Diazoxide (DZX) therapy.
- As a KATP channel agonist, DZX blocks insulin release by keeping the KATP channel open, preventing β-cell depolarization.

KNOWLEDGE GAP: Since DZX acts by suppressing insulin release, concerns arise whether weight gain in infancy will be suppressed while on DZX. Conversely, will awaiting SR result in excessive weight gain in untreated HH infants?

STUDY AIM:
To compare weight change patterns in infants with prolonged HH managed with dextrose infusion awaiting SR versus those who received DZX treatment.

METHODS
Prolonged HH infants met all the following inclusion criteria:
- BG <3.5mmol/L at ≥5d of life
- GIR >10 mg/kg/min to maintain blood glucose (BG) >3.4mmol/L
- Inappropriate insulin levels when BG <3mmol/L
- Hypoketonemia

We excluded infants with sepsis, polycythemia, IEMs, hypocortisolism and growth hormone deficiency.

Resolution of HH in SR infants was confirmed by normal home glucose for 2 weeks following discharge and DZX infants passed fasting studies on completion of treatment.

Data on demographics, birth weight, gestational age, treatment modality and duration, and follow-up body weight were collected.

Birth weight z-scores were determined using Fenton 2013 tables and follow-up body weight z-scores were derived from WHO Multicenter Growth Reference Study 2006 standards. Changes in weight z-score were analyzed. The study was approved by the Institutional Review Board.

CONCLUSION
1. The use of DZX therapy did not suppress weight gain and resulted in weight gain patterns similar to those of SR infants.
2.Awaiting spontaneous resolution did not result in excessive weight gain compared to DZX treated infants.
3. The use of low dose diazoxide (3mg/kg/day) did not prevent catch up weight gain in DZX treated SGA infants.